MATD3.SA Hospital Mater Dei S.A
- Market cap
- BRL 1.51B
- P/E
- 11.5x
- P/B
- 0.97x
- ROE
- 10.4%
- Dividend yield
- 4.98%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MATD3.SA undervalued?
Graham numberMATD3.SA trades 29.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hospital Mater Dei S.A fundamental analysis
No fundamental analysis for Hospital Mater Dei S.A yet.
Hospital Mater Dei S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hospital Mater Dei S.A
Hospital Mater Dei S.A. operates hospitals in Brazil. It engages in data and artificial intelligence business. The company was incorporated in 1973 and is headquartered in Belo Horizonte, Brazil. Hospital Mater Dei S.A. is a subsidiary of JSS Empreendimentos e Administração LTDA.
Full company profileHospital Mater Dei S.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hospital Mater Dei S.A annual financial statements (BRL; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 627M | 733M | 718M | 1.02B | 1.76B | 2.19B | 2.23B | 2.18B | 2.38B |
| Gross Profit | - | 285M | 336M | 290M | 405M | 623M | 712M | 671M | 651M | 721M |
| Operating Income | - | 182M | 219M | 146M | 242M | 338M | 424M | -336M | 354M | 404M |
| EBITDA | - | 236M | 277M | 157M | 342M | 501M | 555M | -156M | 550M | 614M |
| Net Income | - | 124M | 138M | 72.6M | 145M | 104M | 120M | -338M | 111M | 155M |
| EPS | - | 0.35 | 0.39 | 0.20 | 0.38 | 0.27 | 0.31 | -0.96 | 0.33 | 0.47 |
| Balance Sheet | ||||||||||
| Total Assets | 1.02B | 1.20B | 1.32B | 1.18B | 4.09B | 4.93B | 5.17B | 4.34B | 4.31B | 4.38B |
| Total Liabilities | 376M | 457M | 474M | 923M | 2.45B | 3.32B | 3.42B | 2.86B | 2.84B | 2.87B |
| Shareholders' Equity | 647M | 741M | 847M | 261M | 1.64B | 1.62B | 1.66B | 1.45B | 1.46B | 1.49B |
| Cash & Short-term Investments | 156M | 286M | 261M | 271M | 1.28B | 378M | 319M | 675M | 625M | 600M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 179M | 169M | 101M | 80.1M | 153M | -61.7M | 157M | 132M | 224M | 174M |
| Capital Expenditure | 124M | 150M | 97.1M | 75.3M | 336M | 330M | 168M | 200M | 60.9M | 77.1M |
| Free Cash Flow | - | 17.0M | 3.10M | 56.0M | 29.3M | -278M | -10.9M | -68.0M | 163M | 96.5M |
| Ratios | ||||||||||
| ROE | - | 16.8% | 16.3% | 27.8% | 8.8% | 6.4% | 7.2% | -23.4% | 7.5% | 10.4% |
| ROA | - | 10.4% | 10.5% | 6.1% | 3.5% | 2.1% | 2.3% | -7.8% | 2.6% | 3.5% |
| Net Profit Margin | - | 19.9% | 18.9% | 10.1% | 14.1% | 5.9% | 5.5% | -15.2% | 5.1% | 6.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hospital Mater Dei S.A dividends
- Dividend yield
- 4.98%
- Forward dividend
- 0.15 BRL
- Payout ratio
- 68.1%
- Ex-dividend date
- Dec 9, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | BRL 75.3M | 0.23 | 68.1% |
| 2024 | BRL 28.4M | 0.08 | - |
| 2023 | BRL 24.6M | 0.06 | 20.5% |
| 2022 | BRL 59.0M | 0.15 | 57.0% |
| 2021 | BRL 27.3M | 0.07 | 18.8% |
| 2020 | BRL 30.2M | 0.09 | 41.6% |
| 2019 | BRL 47.9M | 0.14 | 34.7% |
| 2018 | BRL 22.1M | 0.06 | 17.8% |
| 2017 | BRL 34.3M | 0.10 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Hospital Mater Dei S.A
- Insiders 82.05%
- Institutions 14.61%
- Public & others 3.34%
- Shares outstanding 330M
- Free float 57.2M
Hospital Mater Dei S.A company profile
- Company name
- Hospital Mater Dei S.A
- Ticker
- MATD3.SA
- ISIN
- BRMATDACNOR4
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- December
- Address
- R Mato Grosso, no 1100, Belo Horizonte, MG, Brazil, 30.190-081
- Phone
- 55 31 3339 9221
- Website
- materdei.com.br
About Hospital Mater Dei S.A
Hospital Mater Dei S.A. operates hospitals in Brazil. It engages in data and artificial intelligence business. The company was incorporated in 1973 and is headquartered in Belo Horizonte, Brazil. Hospital Mater Dei S.A. is a subsidiary of JSS Empreendimentos e Administração LTDA.
Hospital Mater Dei S.A management
7- Mr. Jose Henrique Dias SalvadorChief Executive Officer
- Mr. Rafael Cardoso CordeiroChief Financial & Investor Relations Officer
- Dr. Andre Soares de Moura CostaDirector of Operations
- Mr. Fabio Mascarenhas da SilvaFinancial, Procurement & Administrative Director
- Ms. Renata Salvador GrandeVice President of Sales & Revenue Cycle
- Marcia Fernanda Campos Barreto SampaioDirector of People & Management
- Ms. Maria Fernanda Veloso PiresMember of the Audit & Risk Committee and Board Secretary